A Phase II Open-Label Study of the Clinical Effectiveness of a Human Monoclonal Antibody Against Hepatitis C Virus E2 Glycoprotein (MBL-HCV1) Combined With Oral Direct-Acting Antivirals in Hepatitis C Infected Patients Undergoing Liver Transplantation

Trial Profile

A Phase II Open-Label Study of the Clinical Effectiveness of a Human Monoclonal Antibody Against Hepatitis C Virus E2 Glycoprotein (MBL-HCV1) Combined With Oral Direct-Acting Antivirals in Hepatitis C Infected Patients Undergoing Liver Transplantation

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs MBL HCV1 (Primary) ; Sofosbuvir; Telaprevir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors MassBiologics
  • Most Recent Events

    • 12 Feb 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
    • 12 Feb 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 12 Jan 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrails.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top